Skip to main content
    V

    Vertex Pharmaceuticals Inc (VRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $537.79
    -0.81 (-0.15%)

    Market Cap: $136.56B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vertex Pharmaceuticals Inc (VRTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Vertex Pharmaceuticals reported revenue of $12.00B for the fiscal year ended Dec 31, 2025, up 8.9% from the year before. That year, net income was $3.95B with a net margin of 32.9%, operating cash flow was $3.63B and free cash flow was $3.19B. The quarter ended Sep 30, 2026 had revenue of $3.44B and net income of $653.60M.

    Revenue and Margins

    The operating margin was 34.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.70B, a compound annual rate of 24.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$12.00B+8.9%86.2%34.8%32.9%
    Dec 2024$11.02B+11.7%86.1%-2.1%-4.9%
    Dec 2023$9.87B+10.5%87.2%38.8%36.7%
    Dec 2022$8.93B+17.9%87.9%48.2%37.2%
    Dec 2021$7.57B+22.1%88.1%36.7%30.9%
    Dec 2020$6.21B+49.1%88.1%46.0%43.7%
    Dec 2019$4.16B+36.6%86.8%28.8%28.3%
    Dec 2018$3.05B+22.5%86.6%20.8%68.5%
    Dec 2017$2.49B+46.2%88.9%5.0%3.7%
    Dec 2016$1.70BN/A87.6%0.6%-4.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 39.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$12.00B$11.02B$9.87B$8.93B$7.57B$6.21B$4.16B$3.05B$2.49B$1.70B
    Cost of revenue$1.65B$1.53B$1.26B$1.08B$904.20M$736.30M$547.80M$409.54M$275.12M$210.46M
    Gross profit$10.35B$9.49B$8.61B$7.85B$6.67B$5.47B$3.62B$2.64B$2.21B$1.49B
    Research and development$4.04B$8.26B$3.69B$2.66B$3.05B$1.83B$1.75B$1.42B$1.32B$1.05B
    Operating income$4.17B-$232.90M$3.83B$4.31B$2.78B$2.86B$1.20B$635.15M$123.24M$9.94M
    Net income$3.95B-$535.60M$3.62B$3.32B$2.34B$2.71B$1.18B$2.09B$91.64M-$84.03M
    EBITDA$4.38B-$111.80M$3.99BN/A$2.91B$3.26B$1.50B$706.78MN/A$75.46M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$3.44B$3.33B$2.99B$3.19B$3.08B$2.96B$2.77B$2.91B$2.77B$2.65B$2.69B$2.52B
    Gross profit$2.91B$2.84B$2.59B$2.72B$2.66B$2.56B$2.41B$2.49B$2.38B$2.27B$2.35B$2.15B
    Operating income$712.90M$1.25B$1.14B$1.21B$1.19B$1.15B$630.10M$1.03B$1.12B-$3.51B$1.14B$988.50M
    Net income$653.60M$1.10B$1.03B$1.19B$1.08B$1.03B$646.30M$913.00M$1.05B-$3.59B$1.10B$968.80M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, the balance sheet showed $5.08B in cash and equivalents and no debt.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$25.64B$22.53B$22.73B$18.15B$13.43B$11.75B$8.32B$6.25B$3.55B$2.90B
    Current assets$11.20B$9.60B$14.14B$13.23B$9.56B$8.13B$4.82B$3.84B$2.65B$1.83B
    Cash and equivalents$5.08B$4.57B$10.37B$10.50B$6.79B$5.99B$3.11B$2.65B$1.67B$1.18B
    Total liabilities$6.98B$6.12B$5.15B$4.24B$3.33B$3.06B$2.23B$1.81B$1.50B$1.56B
    Short-term debt$0$92.30M$83.70M$89.40M$80.20M$42.40M$38.79M$9.82M$22.53M$319.43M
    Long-term debt$0N/AN/AN/AN/AN/AN/A$561.89M$563.41M$486.36M
    Shareholder equity$18.67B$16.41B$17.58B$13.91B$10.10B$8.69B$6.09B$4.44B$2.03B$1.16B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$32.74B$27.42B$26.48B$26.14B$24.86B$24.04B$22.88B$22.53B$22.24B$20.13B$23.92B$22.73B
    Total liabilities$11.83B$7.18B$7.12B$7.48B$7.54B$6.86B$6.38B$6.12B$6.61B$5.36B$5.37B$5.15B
    Cash and equivalents$4.98B$6.14B$5.49B$5.09B$4.94B$4.97B$4.67B$4.57B$5.24B$4.58B$9.16B$10.37B
    Shareholder equity$20.91B$20.25B$19.36B$18.67B$17.32B$17.18B$16.50B$16.41B$15.63B$14.77B$18.55B$17.58B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 87.9% of operating cash flow. Share repurchases came to 63.3% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$3.63B-$492.60M$3.54B$4.13B$2.64B$3.25B$1.57B$1.27B$844.94M$236.10M
    Capital expenditures$437.60M$297.70M$200.40M$204.70M$235.00M$259.80M$75.40M$95.45M$99.42M$56.56M
    Free cash flow$3.19B-$790.30M$3.34B$3.93B$2.41B$2.99B$1.49B$1.17B$745.52M$179.54M
    Dividends paidN/AN/AN/AN/A$102.00M$264.95M$10.05M$20.84M$0$0
    Share repurchases$2.02B$1.18B$427.60M$0$1.43B$539.10M$186.00M$350.04M$0$0
    Investing cash flow-$945.40M-$3.77B-$3.14B-$321.10M-$340.90M$99.40M-$1.24B-$202.16M-$483.33M$51.24M
    Financing cash flow-$2.26B-$1.49B-$562.20M-$67.70M-$1.48B-$505.30M$126.80M-$71.22M$68.40M$133.27M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$643.10M$1.13B$1.43B$498.00M$1.24B$1.07B$818.90M$584.60M$1.37B-$3.75B$1.31B$234.60M
    Capital expenditures$97.30M$112.20M$133.40M$149.40M$101.80M$145.70M$40.70M$92.60M$67.70M$69.00M$68.40M$58.10M
    Free cash flow$545.80M$1.01B$1.29B$348.60M$1.14B$927.40M$778.20M$492.00M$1.30B-$3.82B$1.24B$176.50M
    Last 12 quarters

    Frequently Asked Questions About VRTX

    What is Vertex Pharmaceuticals' annual revenue?

    Vertex Pharmaceuticals reported revenue of $12.00B for the fiscal year ended Dec 31, 2025.

    How fast is Vertex Pharmaceuticals' revenue growing?

    Revenue was up 8.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 10.4%.

    Is Vertex Pharmaceuticals profitable?

    Yes. Vertex Pharmaceuticals reported net income of $3.95B for the fiscal year ended Dec 31, 2025, with a net margin of 32.9%.

    How much free cash flow does VRTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $3.63B minus capital expenditures of $437.60M produced free cash flow of $3.19B.

    How much debt does Vertex Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $0 and cash and equivalents of $5.08B.